Nature Communications (Mar 2018)
Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling
- Carla Danussi,
- Promita Bose,
- Prasanna T. Parthasarathy,
- Pedro C. Silberman,
- John S. Van Arnam,
- Mark Vitucci,
- Oliver Y. Tang,
- Adriana Heguy,
- Yuxiang Wang,
- Timothy A. Chan,
- Gregory J. Riggins,
- Erik P. Sulman,
- Frederick Lang,
- Chad J. Creighton,
- Benjamin Deneen,
- C. Ryan Miller,
- David J. Picketts,
- Kasthuri Kannan,
- Jason T. Huse
Affiliations
- Carla Danussi
- Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
- Promita Bose
- Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center
- Prasanna T. Parthasarathy
- Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center
- Pedro C. Silberman
- Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center
- John S. Van Arnam
- Department of Pathology, University of Texas MD Anderson Cancer Center
- Mark Vitucci
- Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine
- Oliver Y. Tang
- Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center
- Adriana Heguy
- Department of Pathology, New York University School of Medicine
- Yuxiang Wang
- Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center
- Timothy A. Chan
- Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center
- Gregory J. Riggins
- Departments of Neurosurgery, Oncology, and Genetic Medicine, Johns Hopkins School of Medicine
- Erik P. Sulman
- Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
- Frederick Lang
- Department of Neurosurgery, University of Texas MD Anderson Cancer Center
- Chad J. Creighton
- Department of Medicine and Dan L. Duncan Comprehensive Cancer Center Division of Biostatistics, Baylor College of Medicine
- Benjamin Deneen
- Department of Neuroscience, Baylor College of Medicine
- C. Ryan Miller
- Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine
- David J. Picketts
- Department of Biochemistry, Microbiology, and Immunology, University of Ottawa
- Kasthuri Kannan
- Department of Pathology, New York University School of Medicine
- Jason T. Huse
- Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
- DOI
- https://doi.org/10.1038/s41467-018-03476-6
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 15
Abstract
ATRX inactivation frequently occurs in glioma. Here, the authors explore the role of ATRX inactivation in oncogenesis, highlighting ATRX deficiency driven epigenomic changes that influence the expression of genes crucial to the oncogenic phenotype.
